This list’s healthcare stocks have high forward P/E ratios. A high forward P/E indicates probable overvaluation or investor confidence in the Company’s anticipated future earnings. The performance of this list is determined using an equally weighted formula. High Forward Price to Earnings (P/E): Healthcare underperformed the S&P 500 by -12.66% over the past year, returning -29.77%. Using the average beta of this list, the risk level is determined to be moderately high.
The Company AngioDynamics, Inc. develops medical technology. The Company’s goals include:
- Increasing patient quality of life.
- Broadening cancer therapy options.
- Reestablishing normal blood flow in the body’s vascular system.
Three global business units (GBUs) make up its product portfolio: Vascular Access (VA), Oncology/Surgery (OS), and Endovascular Therapies (VIT) (VA). The Company offers a variety of products, including Auryon, Thrombectomy, Peripheral Products (Core), BioFlo, Midlines, Peripherally Inserted Central Catheter (PICC), C3 Wave PICC tip location system, Ports, Dialysis Products, Venous Insufficiency, Microwave Ablation, Radiofrequency Ablation, BioSentry Tract Sealant System, IsoLoc Endorectal Balloon, and Alatus Vagina The AlphaVac System, AngioVac venous drainage system, Thrombolytic catheters, and NanoKnife are all part of its Thrombus Management offering. Angiographic Products and Accessories, Drainage Products, and Micro Access Kits are some of its Peripheral Products (Core).
The forward price to EPS for this Company is 883.5556, making it the top-ranked stock on this list.
Compared to the S&P 500, which lost -0.71% last year and -5.66% last month, AngioDynamics Inc. has performed -17.82% over the previous year and -14.64% over the past month.
A multinational healthcare company is Penumbra, Inc. The Company creates, develops, produces, and promotes goods, and its portfolio is centred on treating medical issues in places with a market gap. Its main objectives are developing, producing, and marketing goods for specialized doctors and other healthcare professionals. It is concentrated on creating and expanding its line of products, which includes immersive healthcare, access, and thrombectomy technology. Within its key markets, it has created a product portfolio with seven different product families, seven of which are devoted to its neuro products, which comprise thrombectomy, embolisation, access, and neurosurgical tools. Among its vascular products are embolisation and thrombectomy. The immersive 3D computer-based technology platform is the Company’s offering in the field of healthcare. The Company primarily offers its goods to healthcare providers through its direct sales force in the US, Europe, Canada, and Australia.
The forward price to EPS for this Company is 528.551, making it the second-ranked stock on this list.
Compared to the S&P 500, which went down 16.59% last year and up 18.28% last month, Penumbra Inc. performed 33.70% worse over the past year and 9.30% worse over the previous month.
Benefits management firm Progyny, Inc. In the United States, the Company specializes in family-building and fertility benefits. The Company’s Smart Cycle strategy is how it delivers its value. The Smart Cycle provides:
- All necessary diagnostic testing.
- Access to technology.
- Medical services are required for a member’s whole course of treatment.
In addition to its integrated pharmacy benefits solution, Progyny Rx, which its clients add, it also provides benefits for fertility. Members of Progyny Rx have access to the medicines required for their reproductive treatments. The Company offers care management services as a component of this solution, including formulary plan design, streamlined authorisation, help filling prescriptions, timely delivery of the medications by its network of speciality pharmacies, training in medication administration, pharmacy support services, and patient advocates.
This firm’s forward price to EPS is 231.589, making it the third-ranked stock on this list.
Progyny Inc. has performed -42.79% over the past year and -17.24% over the past month, versus -25.68% and -8.26%, respectively, for the S&P 500.
Warby Parker, Inc
The Company Warby Parker Inc. is based in the US. This eyewear brand sells optical and sunglass frames for both sexes directly to consumers. The business creates technologies and solutions to aid with vision, including eye exams, vision tests, and prescription lenses and glasses sold online and in physical locations across North America. Scratch-resistant lenses on its sunglasses block ultraviolet A (UVA) and ultraviolet B (UVB) radiation. Through its Buy a Pair, Give a Pair initiative, the Company also provides a pair to a needy person. It offers a variety of goods, including accessories, gift cards, new collections, Scout by Warby Parker, contacts, eyeglasses, sunglasses, and sunglasses. It offers both men and women the Barkley, Topper, Lowry, Haskell, Griffin, Quentin, and Crossfield sunglasses brands.
The forward price to EPS for this Company is 223.8017, making it the fourth-ranked stock on this list.
Compared to the S&P 500, which gained 17.11% last year and 10.03% last month, Warby Parker Inc. has performed 0.00% over the previous year and 1.04% over the past month.
Homology Medicines, Inc
A genetic medicine firm in the clinical stages with a focus on treating uncommon genetic illnesses is Homology Medicines, Inc. Among the clinical initiatives of the Company are HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU), HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), also known as Hun disease. Additionally, the Company is investigating several disorders, such as metachromatic leukodystrophy, and developing a gene therapy candidate, HMI-104, from their GTx-mAb platform for treating patients with paroxysmal nocturnal hemoglobinuria (PNH) (MLD). Its platform is made to work with adeno-associated virus vectors produced from human hematopoietic stem cells.
This firm’s forward price to EPS is 215.2778, making it the fifth-ranked stock on this list.
In contrast to the S&P 500’s -64.95% annual performance and -39.52% monthly performance, Homology Medicines Inc. has performed -82.06% over the past year and -48.51% during the past month.